- · A recognition that a medicine that is unaffordable is, in and of itself, unavailable;
- · Brand name medicines imported from Canada—and other Tier One Countries-- are not ‘cheap drugs’. They are instead valid medicines that can provide a vital lifeline of maintenance medicines that would otherwise be denied to millions of Americans;
- · No one, not even the most fervent supporters of personal importation of safe, affordable prescription medicines from licensed, registered pharmacies in Tier One Countries (not just Canada) has ever suggested that personally imported medicines are the sole answer to lower medicine prices in the U.S.;
- · The role of personal importation prescription medicines is not an inherent authority of Pharma not the Food and Drug Administration (FDA), but is within the province of the U.S. Congress to establish the direction of prescription medicine policy, including but not limited to personal importation;
- · Congressional support of personal importation, is evidenced by continuing Congressional initiatives on a number of fronts including appeals to the HHS Secretary to grant waivers, as well as bi-partisan bills on behalf of personal importation;
- · Tell Pharma that when it threatens to curtail its Research and Development, that much of the cost of that R&D is borne by the U.S. Taxpayer, whom, after supporting such R&D, is subject to the highest prices in the industrialized world for their medicines;
- · Take action on the political front. Americans have traditionally expressed their dissatisfaction with the status quo at the ballot box, leading to historic changes in national policies (i.e., social security, anti-trust legislation, Medicare);
“When these steps are taken—and only then—will we remove the burden of paying the highest prices in the industrialized world for our medications,” Hines concludes.